Borys Hrinczenko, MD
Hematology & Oncology · Lansing, MINPI 1376645085
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $900 of the $1,374 with a category attached, or 65.5%. Bayer accounts for 65.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $929 and has fallen 72.0% since, to $260 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 14 payments — averaging $98.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$900
- Amgen$260
- Genentech USA, Inc.$107
- Mirati Therapeutics, Inc.$42
- Tesaro, Inc.$35
- Foundation Medicine, Inc.$29
Across 114 payments — averaging $3532.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$170K
- Amgen$132K
- Incyte Corporation$40K
- Astrazeneca UK Limited$35K
- Eli Lilly$19K
- Bristol Myers Squibb$4K
- plus $2K from 2 others
What the payments were for
- Consulting fees$90066%
- Food & beverage$43231%
- Education$423%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 1 | $900 |
| Amgen | 2 | $260 |
| Genentech USA, Inc. | 7 | $107 |
| Mirati Therapeutics, Inc. | 2 | $42 |
| Tesaro, Inc. | 1 | $35 |
| Foundation Medicine, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stivarga$900
- IMDELLTRA (AMG 757)$141
- Blincyto$120
How this compares
$1,374 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 13 | $184,914 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $82,948 |
| Imatinib Mesylate | 16 | $5,133 |
| Hydroxyurea | 26 | $1,043 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lansing
- Gordon SrkalovicLansing$167K
- Brittani ThomasLansing$7K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.